Next report date
Report period
Q1 2024
EPS estimate
−2.18USD
Revenue estimate
—
−86.07USD
−15.79 MUSD
1.95 M
About First Wave BioPharma, Inc.
Sector
Industry
CEO
James E. Sapirstein
Website
Headquarters
Boca Raton
Employees (FY)
9
Founded
2014
FIGI
BBG00DBBJ4T4
First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of FWBI is 2.74 USD — it has increased by 0.37% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange First Wave BioPharma, Inc. stocks are traded under the ticker FWBI.
First Wave BioPharma, Inc. is going to release the next earnings report on May 20, 2024. Keep track of upcoming events with our Earnings Calendar.
FWBI stock is 10.20% volatile and has beta coefficient of 1.42. Check out the list of the most volatile stocks — is First Wave BioPharma, Inc. there?
FWBI earnings for the last quarter are −9.21 USD per share, whereas the estimation was −11.20 USD resulting in a 17.77% surprise. The estimated earnings for the next quarter are −4.93 USD per share. See more details about First Wave BioPharma, Inc. earnings.
Yes, you can track First Wave BioPharma, Inc. financials in yearly and quarterly reports right on TradingView.
FWBI stock has fallen by 9.27% compared to the previous week, the month change is a 32.18% fall, over the last year First Wave BioPharma, Inc. has showed a 95.26% decrease.
FWBI net income for the last quarter is −4.10 M USD, while the quarter before that showed −3.43 M USD of net income which accounts for −19.42% change. Track more First Wave BioPharma, Inc. financial stats to get the full picture.
Today First Wave BioPharma, Inc. has the market capitalization of 5.53 M, it has decreased by 3.64% over the last week.
No, FWBI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, FWBI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade First Wave BioPharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 9.00 employees. See our rating of the largest employees — is First Wave BioPharma, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So First Wave BioPharma, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating First Wave BioPharma, Inc. stock shows the sell signal. See more of First Wave BioPharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on First Wave BioPharma, Inc. future price: according to them, FWBI price has a max estimate of 36.00 USD and a min estimate of 36.00 USD. Read a more detailed First Wave BioPharma, Inc. forecast: see what analysts think of First Wave BioPharma, Inc. and suggest that you do with its stocks.